



Clinical trial results:

Estudio de fase IIIB, abierto, multinacional, aleatorizado y controlado para demostrar la no inferioridad de la respuesta inmunitaria a la vacuna antimeningocócica (serogrupos A, C, W-135 e Y) conjugada (MenACWY-TT) de GSK Biologicals, administrada por vía intramuscular a los 2, 4 y 12 meses de edad o a los 2, 3, 4 y 12 meses de edad, en comparación con dos vacunas MenC conjugadas y autorizadas, administradas por vía intramuscular a los 2, 4 y 12 meses de edad.

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2009-016841-24 |
| Trial protocol | ES DE EE |
| Global end of trial date | 10 September 2013 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 |
| This version publication date | 22 April 2016 |
| First version publication date | 05 June 2015 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 113369 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01144663 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-000429-PIP01-08 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 03 June 2013 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 22 June 2012 |
| Global end of trial reached? | Yes |
| Global end of trial date | 10 September 2013 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Demostrar, a los 5 meses de edad:

- 1.la no inferioridad del esquema de 3 dosis de la vacuna MenACWY-TT conjugada en comparación con el esquema de 2 dosis de la vacuna MenC-CRM197 conjugada
- 2.la no inferioridad del esquema de 3 dosis de la vacuna MenACWY-TT conjugada, frente al esquema de 2 dosis de la vacuna MenC-TT conjugada
- 3.la no inferioridad del esquema de 2 dosis de la vacuna MenACWY-TT conjugada frente al esquema de 2 dosis de la vacuna MenC-CRM197 conjugada
- 4.la no inferioridad del esquema de 2 dosis de la vacuna MenACWY-TT conjugada, frente al esquema de 2 dosis de la vacuna MenC-TT conjugada

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 30 days after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 01 July 2010 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 12 Months |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------|
| Country: Number of subjects enrolled | Estonia: 34 |
| Country: Number of subjects enrolled | Spain: 1559 |
| Country: Number of subjects enrolled | Germany: 502 |
| Worldwide total number of subjects | 2095 |
| EEA total number of subjects | 2095 |

Notes:

| Subjects enrolled per age group | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 2095 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

| | |
|------------------------------|-------------------------|
| Period 1 title | Primary Vaccination |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | GSK134612A 3-dose Group |

Arm description: -

| | |
|--|-------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Nimenrix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3 and 4 months of age and 1 booster dose at 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

| | |
|--------------------|-------------------------|
| Arm title | GSK134612A 2-dose Group |
| Arm description: - | |
| Arm type | Experimental |

| | |
|--|-------------------|
| Investigational medicinal product name | Nimenrix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age. | |
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Arm title | Menjugate Group |
| Arm description: - | |
| Arm type | Active comparator |
| Investigational medicinal product name | Menjugate® |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age. | |
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Arm title | NeisVac-C Group |
| Arm description: - | |
| Arm type | Active comparator |

| | |
|--|-------------------|
| Investigational medicinal product name | NeisVac-CTM |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

| Number of subjects in period 1 | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group |
|---------------------------------------|-------------------------|-------------------------|-----------------|
| Started | 528 | 524 | 516 |
| Completed | 508 | 517 | 508 |
| Not completed | 20 | 7 | 8 |
| Other (please specify) | 20 | 7 | 8 |

| Number of subjects in period 1 | NeisVac-C Group |
|---------------------------------------|-----------------|
| Started | 527 |
| Completed | 509 |
| Not completed | 18 |
| Other (please specify) | 18 |

Period 2

| | |
|------------------------------|-------------------------|
| Period 2 title | Booster Phase |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Single blind |
| Roles blinded | Subject |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|--|-------------------------|
| Arm title | GSK134612A 3-dose Group |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | Nimenrix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3 and 4 months of age and 1 booster dose at 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

| | |
|--|-------------------------|
| Arm title | GSK134612A 2-dose Group |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | Nimenrix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

| | |
|--|-------------------|
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

| | |
|--|-------------------|
| Arm title | Menjugate Group |
| Arm description: - | |
| Arm type | Active comparator |
| Investigational medicinal product name | Menjugate® |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age. | |
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Arm title | NeisVac-C Group |
| Arm description: - | |
| Arm type | Active comparator |
| Investigational medicinal product name | NeisVac-CTM |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age. | |
| Investigational medicinal product name | Infanrix™ hexa |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Single dose intramuscular injection at 2 4 and 12 months of age. | |
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

| Number of subjects in period 2^[1] | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group |
|---|-------------------------|-------------------------|-----------------|
| Started | 497 | 511 | 503 |
| Completed | 494 | 509 | 498 |
| Not completed | 3 | 2 | 5 |
| Consent withdrawn by subject | - | - | 1 |
| Migrated/moved from study area | 1 | 1 | 1 |
| Lost to follow-up | 2 | 1 | 3 |

| Number of subjects in period 2^[1] | NeisVac-C Group |
|---|-----------------|
| Started | 506 |
| Completed | 505 |
| Not completed | 1 |
| Consent withdrawn by subject | 1 |
| Migrated/moved from study area | - |
| Lost to follow-up | - |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects not returning for a specific visit were not withdrawn and could participate in the subsequent follow-up study. Actual enrolment differed depending on the rate of return for the follow-up study, so not all enrolled subjects came to each visit.

Baseline characteristics

Reporting groups

| | |
|--------------------------------|-------------------------|
| Reporting group title | GSK134612A 3-dose Group |
| Reporting group description: - | |
| Reporting group title | GSK134612A 2-dose Group |
| Reporting group description: - | |
| Reporting group title | Menjugate Group |
| Reporting group description: - | |
| Reporting group title | NeisVac-C Group |
| Reporting group description: - | |

| Reporting group values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group |
|---|-------------------------|-------------------------|-----------------|
| Number of subjects | 528 | 524 | 516 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: weeks | | | |
| arithmetic mean | 8.7 | 8.6 | 8.7 |
| standard deviation | ± 1.54 | ± 1.52 | ± 1.53 |
| Gender categorical Units: Subjects | | | |
| Female | 255 | 273 | 264 |
| Male | 273 | 251 | 252 |

| Reporting group values | NeisVac-C Group | Total | |
|--|-----------------|---------------------------------|--|
| Number of subjects | 527 | 2095 | |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years | | 0 0 0 0 0 0 0 | |

| | | | |
|-------------------|--|---|--|
| 85 years and over | | 0 | |
|-------------------|--|---|--|

| | | | |
|--------------------|--------|------|--|
| Age continuous | | | |
| Units: weeks | | | |
| arithmetic mean | 8.6 | | |
| standard deviation | ± 1.49 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 251 | 1043 | |
| Male | 276 | 1052 | |

End points

End points reporting groups

| | |
|--------------------------------|-------------------------|
| Reporting group title | GSK134612A 3-dose Group |
| Reporting group description: - | |
| Reporting group title | GSK134612A 2-dose Group |
| Reporting group description: - | |
| Reporting group title | Menjugate Group |
| Reporting group description: - | |
| Reporting group title | NeisVac-C Group |
| Reporting group description: - | |
| Reporting group title | GSK134612A 3-dose Group |
| Reporting group description: - | |
| Reporting group title | GSK134612A 2-dose Group |
| Reporting group description: - | |
| Reporting group title | Menjugate Group |
| Reporting group description: - | |
| Reporting group title | NeisVac-C Group |
| Reporting group description: - | |

Primary: Number of subjects with meningococcal polysaccharide C serum bactericidal assay, using baby rabbit complement (rSBA-MenC) titres $\geq 1:8$

| | |
|------------------------------|--|
| End point title | Number of subjects with meningococcal polysaccharide C serum bactericidal assay, using baby rabbit complement (rSBA-MenC) titres $\geq 1:8$ ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| One month after vaccination. | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|-------------------------|-------------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[2] | 0 ^[3] | 0 ^[4] | 0 ^[5] |
| Units: Subjects | | | | |

Notes:

[2] - These results were not available at the time of posting. The record will be updated.

[3] - These results were not available at the time of posting. The record will be updated.

[4] - These results were not available at the time of posting. The record will be updated.

[5] - These results were not available at the time of posting. The record will be updated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|---|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 518 | 523 | 509 | 518 |
| Units: Subjects | | | | |
| Any Pain, D1 (N=518; 523; 509; 517) | 247 | 243 | 243 | 233 |
| Grade 3 Pain, D1 (N=518; 523; 509; 517) | 32 | 33 | 28 | 34 |
| Any Redness, D1 (N=518; 523; 509; 517) | 241 | 229 | 236 | 230 |
| Grade 3 Redness, D1 (N=518; 523; 509; 517) | 9 | 5 | 9 | 5 |
| Any Swelling, D1 (N=518; 523; 509; 517) | 188 | 182 | 179 | 188 |
| Grade 3 Swelling, D1 (N=518; 523; 509; 517) | 6 | 4 | 14 | 6 |
| Any Pain, D2 (N=511; 517; 509; 513) | 212 | 210 | 230 | 214 |
| Grade 3 Pain, D2 (N=511; 517; 509; 513) | 23 | 37 | 23 | 29 |
| Any Redness, D2 (N=511; 517; 509; 513) | 261 | 271 | 283 | 284 |
| Grade 3 Redness, D2 (N=511; 517; 509; 513) | 3 | 5 | 10 | 2 |
| Any Swelling, D2 (N=511; 517; 509; 513) | 211 | 206 | 225 | 210 |
| Grade 3 Swelling, D2 (N=511; 517; 509; 513) | 3 | 6 | 14 | 10 |
| Any Pain, D3 (N=505; 517; 507; 508) | 168 | 180 | 180 | 193 |
| Grade 3 Pain, D3 (N=505; 517; 507; 508) | 13 | 18 | 15 | 22 |
| Any Redness, D3 (N=505; 517; 507; 508) | 247 | 265 | 308 | 274 |
| Grade 3 Redness, D3 (N=505; 517; 507; 508) | 9 | 6 | 13 | 9 |
| Any Swelling, D3 (N=505; 517; 507; 508) | 210 | 216 | 252 | 218 |
| Grade 3 Swelling, D3 (N=505; 517; 507; 508) | 8 | 6 | 11 | 13 |
| Any Pain, Overall (N=518; 523; 509; 518) | 319 | 332 | 344 | 327 |
| Grade 3 Pain, Overall (N=518; 523; 509; 518) | 54 | 67 | 48 | 69 |
| Any Redness, Overall (N=518; 523; 509; 518) | 363 | 369 | 391 | 371 |
| Grade 3 Redness, Overall (N=518; 523; 509; 518) | 18 | 15 | 24 | 15 |

| | | | | |
|--|-----|-----|-----|-----|
| Any Swelling, Overall (N=518; 523; 509; 518) | 326 | 318 | 343 | 317 |
| Grade 3 Swelling, Overall (N=518; 523; 509; 518) | 15 | 11 | 27 | 24 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.

| | |
|-----------------|--|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|---|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 518 | 523 | 509 | 518 |
| Units: Subjects | | | | |
| Any Pain, D1 (N=518; 523; 509; 517) | 161 | 155 | 158 | 157 |
| Grade 3 Pain, D1 (N=518; 523; 509; 517) | 18 | 17 | 12 | 24 |
| Any Redness, D1 (N=518; 523; 509; 517) | 132 | 128 | 138 | 140 |
| Grade 3 Redness, D1 (N=518; 523; 509; 517) | 2 | 1 | 2 | 1 |
| Any Swelling, D1 (N=518; 523; 509; 517) | 68 | 62 | 87 | 82 |
| Grade 3 Swelling, D1 (N=518; 523; 509; 517) | 1 | 0 | 3 | 0 |
| Any Pain, D2 (N=510; 0; 0; 0) | 125 | 0 | 0 | 0 |
| Grade 3 Pain, D2 (N=510; 0; 0; 0) | 9 | 0 | 0 | 0 |
| Any Redness, D2 (N=510; 0; 0; 0) | 131 | 0 | 0 | 0 |
| Grade 3 Redness, D2 (N=510; 0; 0; 0) | 0 | 0 | 0 | 0 |
| Any Swelling, D2 (N=510; 0; 0; 0) | 77 | 0 | 0 | 0 |
| Grade 3 Swelling, D2 (N=510; 0; 0; 0) | 0 | 0 | 0 | 0 |
| Any Pain, D3 (N=505; 516; 507; 508) | 106 | 124 | 130 | 143 |
| Grade 3 Pain, D3 (N=505; 516; 507; 508) | 7 | 11 | 9 | 12 |
| Any Redness, D3 (N=505; 516; 507; 508) | 162 | 169 | 214 | 197 |
| Grade 3 Redness, D3 (N=505; 516; 507; 508) | 0 | 0 | 0 | 1 |
| Any Swelling, D3 (N=505; 516; 507; 508) | 104 | 115 | 137 | 130 |

| | | | | |
|--|-----|-----|-----|-----|
| Grade 3 Swelling, D3 (N=505; 516; 507; 508) | 0 | 1 | 0 | 4 |
| Any Pain, Overall (N=518; 523; 509; 518) | 229 | 202 | 213 | 213 |
| Grade 3 Pain, Overall (N=518; 523; 509; 518) | 29 | 26 | 19 | 33 |
| Any Redness, Overall (N=518; 523; 509; 518) | 233 | 206 | 255 | 233 |
| Grade 3 Redness, Overall (N=518; 523; 509; 518) | 2 | 1 | 2 | 2 |
| Any Swelling, Overall (N=518; 523; 509; 518) | 154 | 136 | 175 | 164 |
| Grade 3 Swelling, Overall (N=518; 523; 509; 518) | 1 | 1 | 3 | 4 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|---|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 518 | 523 | 509 | 517 |
| Units: Subjects | | | | |
| Any Pain, D1 (N=518; 523; 509; 517) | 212 | 202 | 208 | 210 |
| Grade 3 Pain, D1 (N=518; 523; 509; 517) | 28 | 28 | 25 | 32 |
| Any Redness, D1 (N=518; 523; 509; 517) | 201 | 190 | 191 | 192 |
| Grade 3 Redness, D1 (N=518; 523; 509; 517) | 7 | 3 | 6 | 2 |
| Any Swelling, D1 (N=518; 523; 509; 517) | 148 | 148 | 128 | 147 |
| Grade 3 Swelling, D1 (N=518; 523; 509; 517) | 6 | 4 | 13 | 4 |
| Any Pain, D2 (N=511; 517; 509; 513) | 184 | 200 | 219 | 198 |
| Grade 3 Pain, D2 (N=511; 517; 509; 513) | 18 | 34 | 22 | 27 |
| Any Redness, D2 (N=511; 517; 509; 513) | 232 | 250 | 264 | 265 |
| Grade 3 Redness, D2 (N=511; 517; 509; 513) | 1 | 5 | 10 | 2 |

| | | | | |
|--|-----|-----|-----|-----|
| Any Swelling, D2 (N=511; 517; 509; 513) | 182 | 185 | 208 | 195 |
| Grade 3 Swelling, D2 (N=511; 517; 509; 513) | 1 | 3 | 13 | 10 |
| Any Pain, D3 (N=505; 517; 507; 508) | 144 | 159 | 153 | 175 |
| Grade 3 Pain, D3 (N=505; 517; 507; 508) | 9 | 14 | 11 | 19 |
| Any Redness, D3 (N=505; 517; 507; 508) | 228 | 243 | 272 | 247 |
| Grade 3 Redness, D3 (N=505; 517; 507; 508) | 5 | 4 | 11 | 7 |
| Any Swelling, D3 (N=505; 517; 507; 508) | 191 | 200 | 227 | 197 |
| Grade 3 Swelling, D3 (N=505; 517; 507; 508) | 6 | 4 | 11 | 11 |
| Any Pain, Overall (N=518; 523; 509; 518) | 289 | 311 | 314 | 310 |
| Grade 3 Pain, Overall (N=518; 523; 509; 518) | 44 | 58 | 43 | 63 |
| Any Redness, Overall (N=518; 523; 509; 518) | 336 | 344 | 358 | 349 |
| Grade 3 Redness, Overall (N=518; 523; 509; 518) | 13 | 11 | 19 | 10 |
| Any Swelling, Overall (N=518; 523; 509; 518) | 297 | 292 | 308 | 294 |
| Grade 3 Swelling, Overall (N=518; 523; 509; 518) | 12 | 7 | 25 | 21 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|---|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 518 | 523 | 509 | 518 |
| Units: Subjects | | | | |
| Any Pain, D1 (N=518; 523; 509; 517) | 218 | 201 | 217 | 195 |
| Grade 3 Pain, D1 (N=518; 523; 509; 517) | 29 | 26 | 26 | 32 |
| Any Redness, D1 (N=518; 523; 509; 517) | 209 | 184 | 196 | 183 |

| | | | | |
|--|-----|-----|-----|-----|
| Grade 3 Redness, D1 (N=518; 523; 509; 517) | 4 | 2 | 5 | 4 |
| Any Swelling, D1 (N=518; 523; 509; 517) | 135 | 136 | 130 | 120 |
| Grade 3 Swelling, D1 (N=518; 523; 509; 517) | 4 | 1 | 10 | 4 |
| Any Pain, D2 (N=511; 517; 509; 513) | 179 | 186 | 203 | 189 |
| Grade 3 Pain, D2 (N=511; 517; 509; 513) | 20 | 31 | 19 | 25 |
| Any Redness, D2 (N=511; 517; 509; 513) | 197 | 216 | 225 | 235 |
| Grade 3 Redness, D2 (N=511; 517; 509; 513) | 2 | 1 | 5 | 1 |
| Any Swelling, D2 (N=511; 517; 509; 513) | 154 | 162 | 156 | 155 |
| Grade 3 Swelling, D2 (N=511; 517; 509; 513) | 3 | 4 | 8 | 5 |
| Any Pain, D3 (N=505; 517; 507; 508) | 129 | 152 | 132 | 150 |
| Grade 3 Pain, D3 (N=505; 517; 507; 508) | 10 | 13 | 10 | 18 |
| Any Redness, D3 (N=505; 517; 507; 508) | 173 | 213 | 227 | 209 |
| Grade 3 Redness, D3 (N=505; 517; 507; 508) | 4 | 4 | 6 | 2 |
| Any Swelling, D3 (N=505; 517; 507; 508) | 136 | 152 | 164 | 146 |
| Grade 3 Swelling, D3 (N=505; 517; 507; 508) | 3 | 4 | 6 | 5 |
| Any Pain, Overall (N=518; 523; 509; 518) | 285 | 304 | 312 | 291 |
| Grade 3 Pain, Overall (N=518; 523; 509; 518) | 46 | 54 | 41 | 61 |
| Any Redness, Overall (N=518; 523; 509; 518) | 297 | 322 | 331 | 316 |
| Grade 3 Redness, Overall (N=518; 523; 509; 518) | 8 | 7 | 12 | 7 |
| Any Swelling, Overall (N=518; 523; 509; 518) | 247 | 259 | 262 | 237 |
| Grade 3 Swelling, Overall (N=518; 523; 509; 518) | 9 | 7 | 16 | 13 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.

| | |
|-----------------|--|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 491 | 510 | 496 | 503 |
| Units: Subjects | | | | |
| Any Pain | 191 | 203 | 203 | 181 |
| Grade 3 Pain | 24 | 23 | 31 | 18 |
| Any Redness | 186 | 221 | 213 | 228 |
| Grade 3 Redness | 3 | 6 | 5 | 4 |
| Any Swelling | 133 | 152 | 158 | 165 |
| Grade 3 Swelling | 1 | 2 | 2 | 5 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 491 | 510 | 495 | 504 |
| Units: Subjects | | | | |
| Any Pain | 240 | 241 | 242 | 221 |
| Grade 3 Pain | 35 | 33 | 39 | 23 |
| Any Redness | 259 | 286 | 282 | 280 |
| Grade 3 Redness | 29 | 24 | 32 | 22 |
| Any Swelling | 212 | 226 | 244 | 240 |
| Grade 3 Swelling | 20 | 18 | 17 | 14 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.

| | |
|-----------------|---|
| End point title | Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix. |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 491 | 510 | 495 | 504 |
| Units: Subjects | | | | |
| Any Pain | 212 | 215 | 227 | 205 |
| Grade 3 Pain | 36 | 33 | 33 | 26 |
| Any Redness | 219 | 243 | 242 | 251 |
| Grade 3 Redness | 14 | 9 | 20 | 9 |
| Any Swelling | 173 | 174 | 189 | 195 |
| Grade 3 Swelling | 5 | 5 | 4 | 10 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general symptom.

| | |
|-----------------|--|
| End point title | Number of subjects reporting any, grade 3 and related solicited general symptom. |
|-----------------|--|

End point description:

Symptoms were abbreviated as follows: D=Drowsiness; I=Irritability/Fussiness; L=Loss of appetite ; T=Temperature, while vaccine doses were D1=Dose 1, D2 = Dose2, D3 = Dose 3 and Overall = Across doses.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|---|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 518 | 523 | 509 | 518 |
| Units: Subjects | | | | |
| Any D, D1 (N=518; 523; 508; 517) | 298 | 282 | 285 | 297 |
| Grade 3 D, D1 (N=518; 523; 508; 517) | 22 | 22 | 17 | 34 |
| Related D, D1 (N=518; 523; 508; 517) | 163 | 167 | 163 | 178 |
| Any I, D1 (N=518; 523; 508; 517) | 329 | 337 | 355 | 364 |
| Grade 3 I, D1 (N=518; 523; 508; 517) | 54 | 41 | 45 | 54 |
| Related I, D1 (N=518; 523; 508; 517) | 199 | 206 | 213 | 235 |
| Any L, D1 (N=518; 523; 508; 517) | 188 | 208 | 196 | 219 |
| Grade 3 L, D1 (N=518; 523; 508; 517) | 12 | 11 | 9 | 8 |
| Related L, D1 (N=518; 523; 508; 517) | 95 | 106 | 111 | 117 |
| Any T, D1 (N=518; 523; 508; 517) | 166 | 162 | 170 | 183 |
| Grade 3 T, D1 (N=518; 523; 508; 517) | 0 | 0 | 0 | 0 |
| Related T, D1 (N=518; 523; 508; 517) | 128 | 119 | 122 | 144 |
| Any D, D2 (N=511; 515; 509; 512) | 232 | 210 | 231 | 211 |
| Grade 3 D, D2 (N=511; 515; 509; 512) | 20 | 20 | 17 | 12 |
| Related D, D2 (N=511; 515; 509; 512) | 133 | 123 | 137 | 132 |
| Any I, D2 (N=511; 515; 509; 512) | 328 | 312 | 319 | 320 |
| Grade 3 I, D2 (N=511; 515; 509; 512) | 52 | 35 | 44 | 48 |
| Related I, D2 (N=511; 515; 509; 512) | 208 | 198 | 194 | 212 |
| Any L, D2 (N=511; 515; 509; 512) | 164 | 185 | 183 | 179 |
| Grade 3 L, D2 (N=511; 515; 509; 512) | 10 | 6 | 6 | 7 |
| Related L, D2 (N=511; 515; 509; 512) | 95 | 103 | 93 | 106 |
| Any T, D2 (N=511; 515; 509; 512) | 146 | 145 | 158 | 144 |
| Grade 3 T, D2 (N=511; 515; 509; 512) | 1 | 0 | 1 | 1 |
| Related T, D2 (N=511; 515; 509; 512) | 107 | 105 | 116 | 110 |
| Any D, D3 (N=505; 516; 505; 507) | 181 | 194 | 197 | 193 |
| Grade 3 D, D3 (N=505; 516; 505; 507) | 21 | 7 | 13 | 14 |
| Related D, D3 (N=505; 516; 505; 507) | 112 | 115 | 109 | 112 |
| Any I, D3 (N=505; 516; 505; 507) | 259 | 279 | 271 | 262 |
| Grade 3 I, D3 (N=505; 516; 505; 507) | 37 | 30 | 32 | 39 |
| Related I, D3 (N=505; 516; 505; 507) | 165 | 178 | 164 | 174 |
| Any L, D3 (N=505; 516; 505; 507) | 149 | 176 | 159 | 154 |
| Grade 3 L, D3 (N=505; 516; 505; 507) | 14 | 11 | 10 | 9 |
| Related L, D3 (N=505; 516; 505; 507) | 88 | 94 | 83 | 90 |
| Any T, D3 (N=505; 516; 505; 507) | 106 | 127 | 112 | 114 |
| Grade 3 T, D3 (N=505; 516; 505; 507) | 0 | 2 | 2 | 1 |
| Related T, D3 (N=505; 516; 505; 507) | 71 | 88 | 79 | 89 |
| Any D, Overall (N=518; 523; 509; 518) | 376 | 365 | 370 | 377 |
| Grade 3 D, Overall (N=518; 523; 509; 518) | 45 | 41 | 40 | 47 |
| Related D, Overall (N=518; 523; 509; 518) | 235 | 231 | 235 | 237 |
| Any I, Overall (N=518; 523; 509; 518) | 419 | 436 | 439 | 441 |
| Grade 3 I, Overall (N=518; 523; 509; 518) | 109 | 83 | 86 | 104 |
| Related I, Overall (N=518; 523; 509; 518) | 302 | 304 | 311 | 325 |
| Any L, Overall (N=518; 523; 509; 518) | 295 | 325 | 307 | 312 |
| Grade 3 L, Overall (N=518; 523; 509; 518) | 28 | 23 | 22 | 22 |

| | | | | |
|---|-----|-----|-----|-----|
| Related L, Overall (N=518; 523; 509; 518) | 180 | 194 | 186 | 182 |
| Any T, Overall (N=518; 523; 509; 518) | 272 | 274 | 277 | 275 |
| Grade 3 T, Overall (N=518; 523; 509; 518) | 1 | 2 | 3 | 2 |
| Related T, Overall (N=518; 523; 509; 518) | 203 | 208 | 208 | 220 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general symptom.

| | |
|-----------------|--|
| End point title | Number of subjects reporting any, grade 3 and related solicited general symptom. |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|--------------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 491 | 510 | 496 | 504 |
| Units: Subjects | | | | |
| Any Drowsiness | 198 | 206 | 208 | 202 |
| Grade 3 Drowsiness | 14 | 13 | 21 | 18 |
| Related Drowsiness | 125 | 129 | 119 | 125 |
| Any Irritability | 284 | 296 | 284 | 297 |
| Grade 3 Irritability | 41 | 37 | 37 | 45 |
| Related Irritability | 180 | 197 | 181 | 186 |
| Any Loss of appetite | 189 | 193 | 198 | 195 |
| Grade 3 Loss of appetite | 12 | 21 | 23 | 27 |
| Related Loss of appetite | 118 | 114 | 114 | 121 |
| Any Temperature (Rectally) | 187 | 180 | 186 | 170 |
| Grade 3 Temperature (Rectally) | 2 | 2 | 3 | 7 |
| Related Temperature (Rectally) | 133 | 132 | 122 | 125 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs).

| | |
|-----------------|---|
| End point title | Number of subjects reporting any unsolicited adverse events |
|-----------------|---|

(AEs).

End point description:

End point type Secondary

End point timeframe:

Within 31 days (days 0 to 30) after each primary vaccine dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 528 | 524 | 516 | 527 |
| Units: Subjects | | | | |
| Any AE(s) | 293 | 273 | 291 | 280 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs).

End point title Number of subjects reporting any unsolicited adverse events (AEs).

End point description:

End point type Secondary

End point timeframe:

Within 31 days (days 0 to 30) after booster vaccination.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 497 | 511 | 503 | 506 |
| Units: Subjects | | | | |
| Any AE(s) | 179 | 185 | 164 | 167 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs).

End point title Number of subjects reporting serious adverse events (SAEs).

End point description:

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Throughout the entire primary study (Day 0 - Month 16). | |

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 528 | 524 | 516 | 527 |
| Units: Subjects | | | | |
| Any SAE(s) | 1 | 0 | 0 | 0 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs).

| | |
|------------------------|---|
| End point title | Number of subjects reporting serious adverse events (SAEs). |
| End point description: | |

| | |
|--------------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Throughout the entire booster study. | |

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 497 | 511 | 503 | 506 |
| Units: Subjects | | | | |
| Any SAE(s) | 26 | 31 | 25 | 25 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).

| | |
|------------------------|--|
| End point title | Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs). |
| End point description: | |

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 31 days (Days 0-30) post-each primary vaccination dose.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 528 | 524 | 516 | 527 |
| Units: Subjects | | | | |
| Any NOCI(s) | 11 | 6 | 5 | 5 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).

| | |
|-----------------|--|
| End point title | Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs). |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From booster vaccination up to ESFU contact.

| End point values | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group | NeisVac-C Group |
|-----------------------------|----------------------------|----------------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 497 | 511 | 503 | 506 |
| Units: Subjects | | | | |
| Any NOCI(s) | 2 | 2 | 7 | 5 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

- Solicited local and general symptoms: during the 8 day - (Day 0-Day 7) after each vaccination
- Unsolicited adverse events: during the 31 day (Day 0 - Day 30) after each vaccination
- SAEs: throughout the entire study (Day 0 – Month 1)

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 16.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------------------|
| Reporting group title | GSK134612A 3-dose Group |
|-----------------------|-------------------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|-------------------------|
| Reporting group title | GSK134612A 2-dose Group |
|-----------------------|-------------------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|-----------------|
| Reporting group title | Menjugate Group |
|-----------------------|-----------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|-----------------|
| Reporting group title | NeisVac-C Group |
|-----------------------|-----------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| Serious adverse events | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group |
|---|-------------------------|-------------------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 54 / 528 (10.23%) | 56 / 524 (10.69%) | 45 / 516 (8.72%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cerebral haemangioma (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemangioma (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Kawasaki's disease (Booster) | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Kawasaki's disease (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Pyrexia (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 5 / 524 (0.95%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Milk allergy (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Milk allergy (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular retraction (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Balanoposthitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular retraction (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchial hyperreactivity (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchospasm (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngospasm (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhinitis allergic (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchial hyperreactivity (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Apparent life threatening event | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asphyxia | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchospasm (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngospasm (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhinitis allergic (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Breath holding | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Alanine aminotransferase increased subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Concussion (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 4 / 516 (0.78%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn (Booster) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Near drowning (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skull fracture (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Concussion (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 4 / 516 (0.78%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn (Primary) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Near drowning (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Overdose | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skull fracture (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Laryngomalacia | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Plagiocephaly | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Wolff-Parkinson-White syndrome | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Epilepsy (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile convulsion (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epilepsy (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain injury (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile convulsion (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Brain injury (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotonia | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphadenitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Conjunctivitis allergic (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis allergic (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Vomiting (Booster) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aphthous stomatitis (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 2 / 524 (0.38%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia, obstructive (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 3 / 524 (0.57%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting (Primary) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aphthous stomatitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 2 / 524 (0.38%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia, obstructive (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Haematuria (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Haematuria (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle spasms (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sacroiliitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Torticollis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle spasms (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sacroiliitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Torticollis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchitis (Booster) | | | |
| subjects affected / exposed | 5 / 528 (0.95%) | 4 / 524 (0.76%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis (Booster) | | | |
| subjects affected / exposed | 4 / 528 (0.76%) | 2 / 524 (0.38%) | 4 / 516 (0.78%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 2 / 524 (0.38%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchiolitis (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 2 / 524 (0.38%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia (booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 3 / 516 (0.58%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media (Booster) | | | |
| subjects affected / exposed | 3 / 528 (0.57%) | 0 / 524 (0.00%) | 2 / 516 (0.39%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis rotavirus (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 2 / 524 (0.38%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media acute (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasopharyngitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenovirus infection (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal abscess (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atypical pneumonia (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial pyelonephritis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis bacterial (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exanthema subitum (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis bacterial (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis norovirus (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis salmonella (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Genital candidiasis (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hand-foot-and-mouth disease (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes simplex (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral discitis (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral herpes (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis (Booster) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis acute (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rotavirus infection (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection (Booster) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral rash (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchiolitis (Primary) | | | |

| | | | |
|---|------------------|------------------|-----------------|
| subjects affected / exposed | 12 / 528 (2.27%) | 10 / 524 (1.91%) | 9 / 516 (1.74%) |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 10 | 0 / 9 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis (Primary) | | | |
| subjects affected / exposed | 9 / 528 (1.70%) | 4 / 524 (0.76%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 4 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis (Primary) | | | |
| subjects affected / exposed | 6 / 528 (1.14%) | 3 / 524 (0.57%) | 5 / 516 (0.97%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia (Primary) | | | |
| subjects affected / exposed | 3 / 528 (0.57%) | 3 / 524 (0.57%) | 2 / 516 (0.39%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection (Primary) | | | |
| subjects affected / exposed | 4 / 528 (0.76%) | 2 / 524 (0.38%) | 2 / 516 (0.39%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis rotavirus (Primary) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 2 / 524 (0.38%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus bronchiolitis | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 3 / 524 (0.57%) | 2 / 516 (0.39%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 4 / 516 (0.78%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media (Primary) | | | |
| subjects affected / exposed | 3 / 528 (0.57%) | 0 / 524 (0.00%) | 2 / 516 (0.39%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection (Primary) | | | |
| subjects affected / exposed | 3 / 528 (0.57%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 1 / 524 (0.19%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial pyelonephritis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasopharyngitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 2 / 524 (0.38%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media acute (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngitis (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection (Primary) | | | |
| subjects affected / exposed | 2 / 528 (0.38%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenovirus infection (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal abscess (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atypical pneumonia (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis bacterial (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Croup infectious | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epstein-Barr virus infection | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exanthema subitum (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis bacterial (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis norovirus (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis salmonella (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Genital candidiasis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| H1N1 influenza | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hand-foot-and-mouth disease (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 1 / 516 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes simplex (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral discitis (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oral herpes (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteomyelitis | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pertussis | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia respiratory syncytial viral | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rotavirus infection (Primary) | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis (Primary) | | | |
| subjects affected / exposed | 1 / 528 (0.19%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral rash (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 1 / 524 (0.19%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite (Booster) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Decreased appetite (Primary) | | | |
| subjects affected / exposed | 0 / 528 (0.00%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | NeisVac-C Group | | |
|---|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 52 / 527 (9.87%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cerebral haemangioma (Booster) | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebral haemangioma (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Kawasaki's disease (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Kawasaki's disease (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Pyrexia (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia (Primary) | | | |
| subjects affected / exposed | 3 / 527 (0.57%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Milk allergy (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Milk allergy (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Reproductive system and breast disorders | | | |
| Balanoposthitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Testicular retraction (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Balanoposthitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Testicular retraction (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchial hyperreactivity (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Asthma (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchospasm (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Laryngospasm (Booster) | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rhinitis allergic (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchial hyperreactivity (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Apparent life threatening event | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Asphyxia | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Asthma (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchospasm (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Laryngospasm (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rhinitis allergic (Primary) | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Breath holding | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Concussion (Booster) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Contusion (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thermal burn (Booster) | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Near drowning (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skull fracture (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Concussion (Primary) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Contusion (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thermal burn (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Near drowning (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Overdose | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skull fracture (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Congenital, familial and genetic disorders | | | |
| Laryngomalacia | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Plagiocephaly | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Wolff-Parkinson-White syndrome | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Epilepsy (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Febrile convulsion (Booster) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Epilepsy (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Brain injury (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Febrile convulsion (Primary) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain injury (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypotonia | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lymphadenitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eye disorders | | | |
| Conjunctivitis allergic (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Conjunctivitis allergic (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Vomiting (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aphthous stomatitis (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Enteritis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Inguinal hernia, obstructive (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Enteritis (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vomiting (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Aphthous stomatitis (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haematemesis | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Inguinal hernia, obstructive (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rash | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Urticaria | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Haematuria (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haematuria (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Muscle spasms (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sacroiliitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Torticollis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Muscle spasms (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Arthritis (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sacroiliitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Torticollis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Bronchitis (Booster) | | | |
| subjects affected / exposed | 4 / 527 (0.76%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis (Booster) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia (Booster) | | | |
| subjects affected / exposed | 3 / 527 (0.57%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchiolitis (Booster) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchopneumonia (booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Otitis media (Booster) | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis rotavirus (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Otitis media acute (Booster) | | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Upper respiratory tract infection (Booster) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laryngitis (Booster) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nasopharyngitis (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pyelonephritis (Booster) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abscess (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Adenovirus infection (Booster) | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anal abscess (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Atypical pneumonia (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacteraemia (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacterial pyelonephritis (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Conjunctivitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Conjunctivitis bacterial (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Encephalitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Exanthema subitum (Booster) | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis bacterial (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis norovirus (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis salmonella (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Genital candidiasis (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hand-foot-and-mouth disease (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Herpes simplex (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intervertebral discitis (Booster) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung infection (Booster) | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oral herpes (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pharyngitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia bacterial (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis acute (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rotavirus infection (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral infection (Booster) | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral rash (Booster) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchiolitis (Primary) | | | |
| subjects affected / exposed | 14 / 527 (2.66%) | | |
| occurrences causally related to treatment / all | 0 / 14 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchitis (Primary) | | | |
| subjects affected / exposed | 8 / 527 (1.52%) | | |
| occurrences causally related to treatment / all | 0 / 8 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis (Primary) | | | |
| subjects affected / exposed | 3 / 527 (0.57%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia (Primary) | | | |
| subjects affected / exposed | 4 / 527 (0.76%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper respiratory tract infection (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis rotavirus (Primary) | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis (Primary) | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 4 / 527 (0.76%) | | | |
| occurrences causally related to treatment / all | 0 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Respiratory syncytial virus bronchiolitis | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchopneumonia (Primary) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Otitis media (Primary) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urinary tract infection (Primary) | | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Conjunctivitis (Primary) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bacterial pyelonephritis (Primary) | | | | |
| subjects affected / exposed | 2 / 527 (0.38%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nasopharyngitis (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Otitis media acute (Primary) | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 527 (0.38%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Influenza | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laryngitis (Primary) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oral candidiasis | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Viral infection (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abscess (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Adenovirus infection (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anal abscess (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atypical pneumonia (Primary) | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacteraemia (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Conjunctivitis bacterial (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Croup infectious | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Encephalitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Epstein-Barr virus infection | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Exanthema subitum (Primary) | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis bacterial (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis norovirus (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis salmonella (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Genital candidiasis (Primary) | | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| H1N1 influenza | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hand-foot-and-mouth disease (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Herpes simplex (Primary) | | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intervertebral discitis (Primary) | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lung infection (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oral herpes (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Osteomyelitis | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pertussis | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pharyngitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia bacterial (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia respiratory syncytial viral | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis acute | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rotavirus infection (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral rash (Primary) | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite (Booster) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Decreased appetite (Primary) | | | |
| subjects affected / exposed | 1 / 527 (0.19%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | GSK134612A 3-dose Group | GSK134612A 2-dose Group | Menjugate Group |
|---|--------------------------------|--------------------------------|------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 419 / 528 (79.36%) | 436 / 524 (83.21%) | 439 / 516 (85.08%) |
| General disorders and administration site conditions | | | |
| Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 319 / 528 (60.42%) | 332 / 524 (63.36%) | 344 / 516 (66.67%) |
| occurrences (all) | 319 | 332 | 344 |
| Redness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 363 / 528 (68.75%) | 369 / 524 (70.42%) | 391 / 516 (75.78%) |
| occurrences (all) | 363 | 369 | 391 |
| Swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 326 / 528 (61.74%) | 318 / 524 (60.69%) | 343 / 516 (66.47%) |
| occurrences (all) | 326 | 318 | 343 |
| Drowsiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 376 / 528 (71.21%) | 365 / 524 (69.66%) | 370 / 516 (71.71%) |
| occurrences (all) | 376 | 365 | 370 |
| Irritability | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 419 / 528 (79.36%) | 436 / 524 (83.21%) | 439 / 516 (85.08%) |
| occurrences (all) | 419 | 436 | 439 |
| Loss of appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 295 / 528 (55.87%) | 325 / 524 (62.02%) | 307 / 516 (59.50%) |
| occurrences (all) | 295 | 325 | 307 |
| Temperature/(Rectally $\geq 38.0^{\circ}\text{C}$) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 272 / 528 (51.52%) | 274 / 524 (52.29%) | 277 / 516 (53.68%) |
| occurrences (all) | 272 | 274 | 277 |

| | | | |
|--|-------------------|-------------------|-------------------|
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinitis | | | |
| subjects affected / exposed | 32 / 528 (6.06%) | 27 / 524 (5.15%) | 33 / 516 (6.40%) |
| occurrences (all) | 32 | 27 | 33 |
| Infections and infestations | | | |
| Upper respiratory tract infection (post-primary) | | | |
| subjects affected / exposed | 82 / 528 (15.53%) | 86 / 524 (16.41%) | 80 / 516 (15.50%) |
| occurrences (all) | 82 | 86 | 80 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 43 / 528 (8.14%) | 34 / 524 (6.49%) | 46 / 516 (8.91%) |
| occurrences (all) | 43 | 34 | 46 |
| Bronchiolitis | | | |
| subjects affected / exposed | 41 / 528 (7.77%) | 34 / 524 (6.49%) | 33 / 516 (6.40%) |
| occurrences (all) | 41 | 34 | 33 |
| Bronchitis | | | |
| subjects affected / exposed | 34 / 528 (6.44%) | 0 / 524 (0.00%) | 0 / 516 (0.00%) |
| occurrences (all) | 34 | 0 | 0 |
| Upper respiratory tract infection (post-booster) | | | |
| subjects affected / exposed | 38 / 528 (7.20%) | 54 / 524 (10.31%) | 53 / 516 (10.27%) |
| occurrences (all) | 38 | 54 | 53 |

| | | | |
|---|--------------------|--|--|
| Non-serious adverse events | NeisVac-C Group | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 441 / 527 (83.68%) | | |
| General disorders and administration site conditions | | | |
| Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 327 / 527 (62.05%) | | |
| occurrences (all) | 327 | | |
| Redness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 371 / 527 (70.40%) | | |
| occurrences (all) | 371 | | |
| Swelling | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|--------------------|--|--|
| subjects affected / exposed | 317 / 527 (60.15%) | | |
| occurrences (all) | 317 | | |
| Drowsiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 377 / 527 (71.54%) | | |
| occurrences (all) | 377 | | |
| Irritability | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 441 / 527 (83.68%) | | |
| occurrences (all) | 441 | | |
| Loss of appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 312 / 527 (59.20%) | | |
| occurrences (all) | 312 | | |
| Temperature/(Rectally $\geq 38.0^{\circ}\text{C}$) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 275 / 527 (52.18%) | | |
| occurrences (all) | 275 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 527 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Upper respiratory tract infection (post-primary) | | | |
| subjects affected / exposed | 74 / 527 (14.04%) | | |
| occurrences (all) | 74 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 36 / 527 (6.83%) | | |
| occurrences (all) | 36 | | |
| Bronchiolitis | | | |
| subjects affected / exposed | 44 / 527 (8.35%) | | |
| occurrences (all) | 44 | | |
| Bronchitis | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 31 / 527 (5.88%) | | |
| occurrences (all) | 31 | | |
| Upper respiratory tract infection (post-booster) | | | |
| subjects affected / exposed | 44 / 527 (8.35%) | | |
| occurrences (all) | 44 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 06 December 2010 | <p>An inconsistency between inclusion criteria and Table 5 was noticed and Table 5 has been corrected according to inclusion criteria.</p> <p>The age for administration of the booster dose has been clarified.</p> <p>Procedure for reporting Guillain Barre syndrome (GBS) has been added.</p> <p>New cold chain deviation wording has been incorporated.</p> |
| 25 May 2011 | <p>The sample size of the study population is increased by approximately 50%, i.e., 680 additional subjects will be enrolled in the study to reach the target samples size of 1650 evaluable subjects to demonstrate the co-primary objectives of this study.</p> <p>The serum bactericidal assay (SBA) is a functional measure of the ability of antibodies in conjunction with complement to kill bacteria and is considered the assay of choice for measurement of functional anti-meningococcal antibodies in vitro. It is well known that, as there is no standardized SBA testing, the inter-laboratory variability could have an important impact on the measured bactericidal titers. Depending on the laboratory where the SBA testing is to be performed, differences around 1% in the percentage of subjects with seroprotective titers may occur. It has been estimated that 50% sample size increase would be necessary to demonstrate all the sequential co-primary objectives regardless of the laboratory where the testing is performed.</p> <p>The primary endpoint of the current study is to assess the immunogenicity induced by the components of the investigational vaccine in terms of rSBA titres $\geq 1:8$ for each of the four serogroups (A, C, W-135 and Y) in all subjects, one month after the final priming vaccination. In addition, rSBA titres $\geq 1:8$ and $\geq 1:128$ will also be assessed at any blood sampling time point during the study in a subset of subjects in all vaccine groups as secondary endpoints. To support the data obtained by rSBA testing, hSBA testing will also be performed and in addition antibody concentrations against meningococcal polysaccharides (PS) are planned to be assessed by ELISA (anti-PS testing). Now, GSK Biologicals decided not to perform anti-PS testing at any blood sampling time point for the following reasons:</p> <ul style="list-style-type: none">- the World Health Organization (WHO) considers SBA the primary means of assessing immune response to meningococcal conjugate vaccines [WHO, 2006; WHO, 1999]. |
| 30 July 2012 | <p>A measles outbreak in Spain impacted 2 centers participating in the study and the local authorities recommended vaccinating subjects from 9 months old onwards. The protocol is amended to allow administration of Measles, Mumps, Rubella (MMR) or Measles, Mumps, Rubella and Varicella (MMRV) vaccine throughout the study in line with local governmental recommendations. It is preferable that the vaccine not be given within 30 days prior or after a dose of study vaccine (with the day of vaccination considered Day 0).</p> <p>The introduction was updated with the current licensing status of MenACWY-TT and competitor vaccines.</p> <p>Several sections were updated to clarify that the Immune Mediated Disease (IMD) report should only be used in case of Guillain-Barre syndrome (GBS).</p> |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported